NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Bicycle Therapeutics logo
$3.20 +0.02 (+0.63%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.19 -0.01 (-0.19%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Advanced

Key Stats

Today's Range
$3.12
▼
$3.22
50-Day Range
$3.18
▼
$4.01
52-Week Range
$3.07
▼
$7.83
Volume
445,392 shs
Average Volume
410,026 shs
Market Capitalization
$224.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.57
Consensus Rating
Hold

Company Overview

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts.

The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.

Its research includes Bicycle toxin conjugates, which pair target-binding peptides with therapeutic payloads, as well as radiopharmaceutical and immune-modulating approaches. The company’s products are investigational and are being developed through clinical and preclinical research.

AI Generated. May Contain Errors.

Bicycle Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

BCYC MarketRank™: 
2.739095638255 of 5 stars

Bicycle Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 432nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicycle Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Bicycle Therapeutics has a consensus price target of $13.57, representing about 324.1% upside from its current price of $3.20.

  • Amount of Analyst Coverage

    Bicycle Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bicycle Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.30) to ($2.35) per share.

  • Price to Book Value per Share Ratio

    Bicycle Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.07% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 8.38.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently increased by 11.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bicycle Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicycle Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Bicycle Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,848.00 in company stock.

  • Percentage Held by Insiders

    22.00% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bicycle Therapeutics' insider trading history.
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCYC Stock News Headlines

Bicycle Therapeutics (NASDAQ:BCYC) Cut to Sell at Wall Street Zen
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Bicycle Therapeutics Ltd. ADR
See More Headlines

BCYC Stock Analysis - Frequently Asked Questions

Bicycle Therapeutics' stock was trading at $7.08 on January 1st, 2026. Since then, BCYC shares have decreased by 54.8% and is now trading at $3.20.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) posted its earnings results on Thursday, October, 29th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.25. The business had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million. Bicycle Therapeutics had a negative net margin of 169.75% and a negative trailing twelve-month return on equity of 26.02%.

Bicycle Therapeutics (BCYC) raised $65 million in an IPO on Thursday, May 23rd 2019. The company issued 4,333,333 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Bicycle Therapeutics' top institutional shareholders include Marshall Wace LLP (1.19%), Pinnacle Associates Ltd. (0.23%), Goldman Sachs Group Inc. (0.14%) and Jump Financial LLC (0.12%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Alistair Milnes, Michael Skynner, Jennifer Scott Perry, Alethia Young, Santiago Arroyo, Travis Alvin Thompson, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett and Robert Charles Swanton.
View institutional ownership trends
.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Rocket Pharmaceuticals (RCKT), Allogene Therapeutics (ALLO), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), Palantir Technologies (PLTR) and PayPal (PYPL).

Company Calendar

Last Earnings
10/29/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCYC
CIK
1761612
Fax
N/A
Employees
288
Year Founded
2009

Price Target and Rating

High Price Target
$36.00
Low Price Target
$7.00
Potential Upside/Downside
+324.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$218.96 million
Net Margins
-169.75%
Pretax Margin
-166.52%
Return on Equity
-26.02%
Return on Assets
-22.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.09
Quick Ratio
12.09

Sales & Book Value

Annual Sales
$72.86 million
Price / Sales
3.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.21 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
70,090,000
Free Float
54,673,000
Market Cap
$224.29 million
Optionable
Optionable
Beta
1.59

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:BCYC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners